Vaxcyte (NASDAQ:PCVX) CAO Sells $180,000.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CAO Elvia Cowan sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total value of $180,000.00. Following the completion of the sale, the chief accounting officer directly owned 28,975 shares of the company’s stock, valued at $1,738,500. The trade was a 9.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elvia Cowan also recently made the following trade(s):

• On Tuesday, March 17th, Elvia Cowan sold 1,892 shares of Vaxcyte stock. The shares were sold at an average price of $55.57, for a total value of $105,138.44.
• On Wednesday, March 11th, Elvia Cowan sold 2,500 shares of Vaxcyte stock. The shares were sold at an average price of $58.59, for a total value of $146,475.00.

Vaxcyte Price Performance

NASDAQ:PCVX opened at $60.88 on Friday. The firm has a market capitalization of $8.76 billion, a price-to-earnings ratio of -10.83 and a beta of 1.38. Vaxcyte, Inc. has a 1 year low of $27.80 and a 1 year high of $65.00. The business has a 50 day simple moving average of $57.29 and a 200-day simple moving average of $49.30.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.46) by ($0.34). During the same quarter last year, the company earned ($1.12) earnings per share. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

Institutional investors and hedge funds have recently bought and sold shares of the company. Smartleaf Asset Management LLC raised its position in Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after purchasing an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in Vaxcyte by 1,463.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after purchasing an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after purchasing an additional 184 shares in the last quarter. Allworth Financial LP raised its position in Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after purchasing an additional 731 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new stake in Vaxcyte during the 3rd quarter valued at $45,000. 96.78% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on PCVX shares. Needham & Company LLC raised their price target on Vaxcyte from $90.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Guggenheim reissued a “buy” rating and set a $116.00 price target on shares of Vaxcyte in a research note on Monday, February 2nd. BTIG Research raised their price target on Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.